Table 1.
Patients characteristics
| n = 335 | |
|---|---|
| Male / Female, n (%) | 233 (70) / 102 (30) |
| Age (years) | 62 ± 11 |
| BMI (kg/m2) | 24.8 ± 3.8 |
| Hypertension, n (%) | 224 (67) |
| Diabetes mellitus, n (%) | 92 (28) |
| HbA1c (%) | 6.1 ± 0.9 |
| Current smoking, n (%) | 26 (7.8) |
| Dyslipidemia, n (%) | 269 (80) |
| eGFR (ml/min/1.73 m2) | 69 ± 17 |
| CKD Stage 3≥, n (%) | 89 (27) |
| Number of risk factors | 4.0 ± 1.5 |
| Cardiovascular disease, n (%) | 100 (30) |
| Coronary artery disease | 87 (26) |
| Cerebral infarction | 12 (3.6) |
| Aortic dissection/aortic aneurysm | 4 (1.2) |
| Peripheral arterial disease | 3 (0.9) |
| Concomitant drug, n (%) | |
| Anti-platelets | 101 (30) |
| ACEs/ARBs | 191 (57) |
| β blockers | 77 (23) |
| Calcium channel blockers | 183(55) |
| Lipid-modifying drugs | 201(60) |
| Statins | 179 (53) |
| Fibrates | 8 (2.4) |
| Ezetimibe | 15 (4.5) |
BMI body mass index, Hb hemoglobin, e-GFR estimated glomerular flow rate, CKD chronic kidney disease, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker